Alectinib

Summary

Alectinib (CHEMBL1738797) is an approved small-molecule EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor (ATC L01ED03) targeting MET and ALK; indicated across 27 conditions including neoplasm and non-small cell lung carcinoma; with CIViC clinical evidence for 32 variant-indication associations (e.g. ALK Fusion in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01ED03
• Targets: 2 (MET, ALK)
• Indications: 27 conditions
• Clinical trials: 67
• Precision-oncology evidence (CIViC): 32 variant–indication associations
• Chemistry: 482.6 Da · C30H34N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1738797
Name	Alectinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	49806720
ChEBI	CHEBI:90936
ATC	L01ED03
Molecular formula	C30H34N4O2
Molecular weight	482.6
InChIKey	KDGFLJKFZUIJMX-UHFFFAOYSA-N

SMILES: CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C

IUPAC name: 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

ChEBI definition: An organic heterotetracyclic compound that is 6,6-dimethyl-5,6-dihydro-11H-benzo[b]carbazol-11-one carrying additional cyano, 4-(morpholin-4-yl)piperidin-1-yl and ethyl substituents at positions 3, 8 and 9 respectively. Used (as the hydrochloride salt) for the treatment of patients with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer.

Pharmacological roles (ChEBI): EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, antineoplastic agent.

Also known as: AF-802, AF802, Alecensa, Alectinib, CH-5424802, CH5424802, RO-5424802, RO5424802, ALECTINIB, CH 5424802, ALECTINIB HYDROCHLORIDE, ALECENSA

Parent form; salt/anhydrous children: CHEMBL3707320

Patent coverage: 2,824 distinct patent families (6,731 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,207 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MET	MET proto-oncogene, receptor tyrosine kinase	Inhibition	5.3	2.4%	P08581
ALK	ALK receptor tyrosine kinase	Inhibition	8.72	0.8%	Q9UM73

Broader ChEMBL bioactivity targets: 33 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Epidermal growth factor receptor, Proto-oncogene tyrosine-protein kinase receptor Ret, D(1A) dopamine receptor, Estrogen receptor, Progesterone receptor, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, D(3) dopamine receptor, Phosphorylase b kinase gamma catalytic chain, liver/testis isoform.

Bioactivity

ChEMBL activities: 97 potent at pChembl ≥ 5 of 101 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ALK	9.23	IC50	0.59	nM	CHEMBL_ACT_22775265
ALK	9.02	IC50	0.96	nM	CHEMBL_ACT_22775391
ALK	8.82	IC50	1.5	nM	CHEMBL_ACT_22775387
ALK	8.81	IC50	1.56	nM	CHEMBL_ACT_24867175
ALK	8.72	IC50	1.9	nM	CHEMBL_ACT_19036772
ALK	8.72	IC50	1.9	nM	CHEMBL_ACT_19145426
ALK	8.72	IC50	1.9	nM	CHEMBL_ACT_24867174
ALK	8.72	IC50	1.9	nM	CHEMBL_ACT_7997506
EML4	8.7	IC50	2	nM	CHEMBL_ACT_16426638
EML4	8.7	IC50	2	nM	CHEMBL_ACT_16426656
EML4	8.7	IC50	2	nM	CHEMBL_ACT_16427358
ALK	8.68	IC50	2.07	nM	CHEMBL_ACT_19145475
ALK	8.55	IC50	2.8	nM	CHEMBL_ACT_29154955
ALK	8.54	IC50	2.9	nM	CHEMBL_ACT_29065666
EML4	8.52	IC50	3	nM	CHEMBL_ACT_16427309
ALK	8.41	IC50	3.9	nM	CHEMBL_ACT_22775383
EML4	8.35	IC50	4.5	nM	CHEMBL_ACT_19145445
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_16655171
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_24867179
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_25935697
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_25935698
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_25935699
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_25935700
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_25935701
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_25935702
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_29065580
ALK	8.28	IC50	5.3	nM	CHEMBL_ACT_17704364
RET	8.24	IC50	5.7	nM	CHEMBL_ACT_24867185
RET	8.08	IC50	8.3	nM	CHEMBL_ACT_24867184
EML4	8.05	IC50	9	nM	CHEMBL_ACT_16427340

Target pathways

Aggregated over 2 target gene(s): MET, ALK.

Top Reactome pathways

57 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	ALK, MET
Disease	2	ALK, MET
Diseases of signal transduction by growth factor receptors and second messengers	2	ALK, MET
Signaling by Receptor Tyrosine Kinases	2	ALK, MET
PIP3 activates AKT signaling	1	MET
Developmental Biology	1	MET
Negative regulation of the PI3K/AKT network	1	MET
Signaling by ALK	1	ALK
Generic Transcription Pathway	1	MET
PI3K/AKT Signaling in Cancer	1	MET
Constitutive Signaling by Aberrant PI3K in Cancer	1	MET
Semaphorin interactions	1	MET
Sema4D in semaphorin signaling	1	MET
Sema4D mediated inhibition of cell attachment and migration	1	MET
Axon guidance	1	MET
Infectious disease	1	MET
RAF/MAP kinase cascade	1	MET
MAPK family signaling cascades	1	MET
MAPK1/MAPK3 signaling	1	MET
Signaling by MET	1	MET
MET Receptor Activation	1	MET
Negative regulation of MET activity	1	MET
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	MET
RNA Polymerase II Transcription	1	MET
Gene expression (Transcription)	1	MET
MET activates RAS signaling	1	MET
MET activates PI3K/AKT signaling	1	MET
MET activates PTPN11	1	MET
MET activates PTK2 signaling	1	MET
InlB-mediated entry of Listeria monocytogenes into host cell	1	MET

Dominant GO biological processes

GO term	Targets
cell surface receptor protein tyrosine kinase signaling pathway	2
protein phosphorylation	2
signal transduction	2
endothelial cell morphogenesis	1
liver development	1
cell surface receptor signaling pathway	1
negative regulation of autophagy	1
neuron differentiation	1
pancreas development	1
positive regulation of transcription by RNA polymerase II	1
hepatocyte growth factor receptor signaling pathway	1
branching morphogenesis of an epithelial tube	1
positive chemotaxis	1
excitatory postsynaptic potential	1
semaphorin-plexin signaling pathway	1

Indications & clinical

Indications

27 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
thyroid gland papillary carcinoma	2	MONDO:0005075	EFO:0000641
sarcoma	2	MONDO:0005089	EFO:0000691
melanoma	2	MONDO:0005105	EFO:0000756
anaplastic large cell lymphoma	2	MONDO:0020325	EFO:0003032
salivary gland cancer	2	MONDO:0004669	EFO:0003826
brain neoplasm	2	MONDO:0021211	EFO:0003833
pancreatic neoplasm	2	MONDO:0021040	EFO:0003860
ovarian neoplasm	2	MONDO:0021068	EFO:0003893
colorectal neoplasm	2	MONDO:0005335	EFO:0004142
upper aerodigestive tract neoplasm	2	MONDO:0005398	EFO:0004284
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
bronchial neoplasm	2	MONDO:0002807	EFO:1000849
lung neoplasm	2	MONDO:0021117	MONDO:0021117
lymphoid neoplasm	2	MONDO:0005157	EFO:0001642
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
respiratory system disorder	2	MONDO:0005087	EFO:0000684
thyroid tumor	2	MONDO:0015074	EFO:0003841
respiratory tract neoplasm	2	MONDO:0020641	EFO:0003853
digestive system neoplasm	2	MONDO:0021223	EFO:0008549
intestinal cancer	2	MONDO:0005814	MONDO:0021118
liver disorder	1	MONDO:0005154	EFO:0001421
glioblastoma	1	MONDO:0018177	EFO:0000519
central nervous system cancer	1	MONDO:0002714	EFO:0000326
hepatocellular carcinoma	1	MONDO:0007256	EFO:0000182

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 67.

Phase distribution

Phase	Trials
PHASE2	24
Not specified	12
PHASE1/PHASE2	11
PHASE3	8
PHASE1	7
PHASE2/PHASE3	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05525338	PHASE4	RECRUITING	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
NCT02838420	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT03178552	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03194893	PHASE3	ACTIVE_NOT_RECRUITING	A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
NCT03768063	PHASE3	ACTIVE_NOT_RECRUITING	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT05170204	PHASE3	ACTIVE_NOT_RECRUITING	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05722886	PHASE2/PHASE3	RECRUITING	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05770037	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT06765109	PHASE3	RECRUITING	Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT02075840	PHASE3	COMPLETED	A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
NCT02604342	PHASE3	COMPLETED	Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
NCT03596866	PHASE3	COMPLETED	A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT02925234	PHASE2	RECRUITING	The Drug Rediscovery Protocol (DRUP Trial)
NCT03202940	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
NCT03944772	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT04116541	PHASE2	RECRUITING	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
NCT04302025	PHASE2	RECRUITING	A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
NCT04322890	PHASE2	RECRUITING	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04341181	PHASE2	RECRUITING	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT04423185	PHASE2	RECRUITING	PLATFORM Study of Precision Medicine for Rare Tumors
NCT04589845	PHASE2	ACTIVE_NOT_RECRUITING	Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04774718	PHASE1/PHASE2	RECRUITING	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT05015010	PHASE2	ACTIVE_NOT_RECRUITING	Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
NCT05159245	PHASE2	RECRUITING	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
NCT05713006	PHASE1/PHASE2	RECRUITING	Alectinib Pharmacokinetic in Patients With NSCLC
NCT05725200	PHASE2	RECRUITING	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
NCT05987644	PHASE1/PHASE2	RECRUITING	Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT06624059	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06692491	PHASE2	NOT_YET_RECRUITING	Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
NCT07560410	PHASE1/PHASE2	NOT_YET_RECRUITING	Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)
NCT01801111	PHASE1/PHASE2	COMPLETED	A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
NCT01871805	PHASE1/PHASE2	COMPLETED	A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
NCT02091141	PHASE2	COMPLETED	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
NCT02314481	PHASE2	COMPLETED	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
NCT02521051	PHASE1/PHASE2	TERMINATED	Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
NCT03131206	PHASE1/PHASE2	TERMINATED	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
NCT03155009	PHASE2	COMPLETED	A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
NCT03158389	PHASE1/PHASE2	COMPLETED	NCT Neuro Master Match - N²M² (NOA-20)
NCT03445000	PHASE2	TERMINATED	ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
NCT03498521	PHASE2	COMPLETED	A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Clinical evidence (CIViC)

Variant × indication × effect (32 predictive associations from 41 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
ALK Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Alectinib	CIViC A	EID12012 +8
ALK Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Crizotinib + Alectinib	CIViC B	EID4858
ALK Fusion	Gastrointestinal Carcinoma	Sensitivity/Response	Alectinib + Crizotinib + Entrectinib	CIViC C	EID10324
EML4::ALK Fusion	Malignant Pleural Mesothelioma	Sensitivity/Response	Alectinib	CIViC C	EID9228
FUS::TFCP2 Fusion AND ALK Exon 2-18 Deletion	Spindle Cell Rhabdomyosarcoma	Sensitivity/Response	Alectinib	CIViC C	EID12406
KANK4::ALK Fusion	Pancreatic Acinar Cell Adenocarcinoma	Sensitivity/Response	Alectinib	CIViC C	EID10327
RET Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Alectinib	CIViC C	EID4850
ALK I1171	Lung Non-small Cell Carcinoma	Resistance	Alectinib	CIViC C	EID1283 +1
ALK I1171N AND HIP1::ALK Fusion	Lung Non-small Cell Carcinoma	Resistance	Alectinib + Crizotinib	CIViC C	EID1483
EML4::ALK Fusion AND ALK I1171N AND ALK L1196M	Malignant Pleural Mesothelioma	Resistance	Alectinib	CIViC C	EID11115
EML4::ALK Fusion AND ALK I1171S	Lung Non-small Cell Carcinoma	Resistance	Alectinib + Crizotinib	CIViC C	EID1484
ALK Alternative Transcript (ATI)	Melanoma	Sensitivity/Response	Ceritinib + Crizotinib + Alectinib + ALK Inhibitor ASP3026 + Entrectinib	CIViC D	EID7484
ALK F1174L	Neuroblastoma	Sensitivity/Response	Alectinib	CIViC D	EID37
EML4::ALK Fusion AND ALK L1196M	Lung Non-small Cell Carcinoma	Sensitivity/Response	Alectinib	CIViC D	EID141
EML4::ALK Fusion AND ALK L1196M	Cancer	Sensitivity/Response	Brigatinib + Lorlatinib + Alectinib + Ceritinib	CIViC D	EID7597
ALK F1174L AND NPM1::ALK Fusion	Cancer	Resistance	Alectinib	CIViC D	EID12665
ALK G1269A AND NPM1::ALK Fusion	Cancer	Resistance	Alectinib	CIViC D	EID12664
ALK G1269A AND v::ALK Fusion	Cancer	Resistance	Alectinib	CIViC D	EID1354
EML4::ALK Fusion AND ABCB1 Overexpression	Lung Adenocarcinoma	Resistance	Lorlatinib + Alectinib	CIViC D	EID10016
EML4::ALK Fusion AND ALK C1156Y	Cancer	Resistance	Lorlatinib + Alectinib + Ceritinib + Brigatinib	CIViC D	EID7609
EML4::ALK Fusion AND ALK F1174L	Cancer	Resistance	Alectinib	CIViC D	EID12666
EML4::ALK Fusion AND ALK G1202R	Cancer	Resistance	Alectinib	CIViC D	EID1350
EML4::ALK Fusion AND ALK G1202R AND ALK L1196M	Cancer	Resistance	Brigatinib + Crizotinib + Lorlatinib + Alectinib + Ceritinib	CIViC D	EID7592
EML4::ALK Fusion AND ALK G1202R AND ALK L1198F	Cancer	Resistance	Alectinib + Lorlatinib + Brigatinib + Ceritinib	CIViC D	EID7595
EML4::ALK Fusion AND ALK G1269A	Cancer	Resistance	Alectinib	CIViC D	EID12669
EML4::ALK Fusion AND ALK I1171S	Cancer	Resistance	Alectinib	CIViC D	EID12670
EML4::ALK Fusion AND ALK R1192P	Cancer	Resistance	Alectinib	CIViC D	EID12667
EML4::ALK Fusion AND ALK T1151M	Cancer	Resistance	Alectinib	CIViC D	EID12668
EML4::ALK Fusion AND ALK T1151dup	Lung Non-small Cell Carcinoma	Resistance	Alectinib	CIViC D	EID1347
EML4::ALK Fusion AND ALK V1180L	Lung Non-small Cell Carcinoma	Resistance	Alectinib	CIViC D	EID1286

+2 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

102 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, MET
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, MET
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, MET
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, MET
BOSUTINIB	ChEMBL	Phase 4 (approved)	ALK, MET
BRIGATINIB	ChEMBL	Phase 4 (approved)	ALK, MET
CERITINIB	ChEMBL	Phase 4 (approved)	ALK, MET
ENTRECTINIB	ChEMBL	Phase 4 (approved)	ALK, MET
ERLOTINIB	ChEMBL	Phase 4 (approved)	ALK, MET
FEDRATINIB	ChEMBL	Phase 4 (approved)	ALK, MET
INFIGRATINIB	ChEMBL	Phase 4 (approved)	ALK, MET
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	ALK, MET
NINTEDANIB	ChEMBL	Phase 4 (approved)	ALK, MET
PALBOCICLIB	ChEMBL	Phase 4 (approved)	ALK, MET
SUNITINIB	ChEMBL	Phase 4 (approved)	ALK, MET
VANDETANIB	ChEMBL	Phase 4 (approved)	ALK, MET
CANERTINIB	ChEMBL	Phase 3	ALK, MET
CEDIRANIB	ChEMBL	Phase 3	ALK, MET
DACTOLISIB	ChEMBL	Phase 3	ALK, MET
LESTAURTINIB	ChEMBL	Phase 3	ALK, MET
LINIFANIB	ChEMBL	Phase 3	ALK, MET
QUERCETIN	ChEMBL	Phase 3	ALK, MET
BEMCENTINIB	ChEMBL	Phase 2	ALK, MET
BI-2536	ChEMBL	Phase 2	ALK, MET
BMS-754807	ChEMBL	Phase 2	ALK, MET
CENISERTIB	ChEMBL	Phase 2	ALK, MET
ENVONALKIB	ChEMBL	Phase 2	ALK, MET
FORETINIB	ChEMBL	Phase 2	ALK, MET
ILORASERTIB	ChEMBL	Phase 2	ALK, MET
OSI-632	ChEMBL	Phase 2	ALK, MET
PELITINIB	ChEMBL	Phase 2	ALK, MET
R-406	ChEMBL	Phase 2	ALK, MET
SU-014813	ChEMBL	Phase 2	ALK, MET
TOZASERTIB	ChEMBL	Phase 2	ALK, MET
Idelalisib	PubChem	Approved	ALK, MET
Selumetinib	PubChem	Approved	ALK, MET
AFATINIB DIMALEATE	ChEMBL	Phase 4 (approved)	MET
AXITINIB	ChEMBL	Phase 4 (approved)	MET
CABOZANTINIB	ChEMBL	Phase 4 (approved)	MET
CABOZANTINIB S-MALATE	ChEMBL	Phase 4 (approved)	MET
CAPMATINIB	ChEMBL	Phase 4 (approved)	MET
DABRAFENIB	ChEMBL	Phase 4 (approved)	MET
ENSARTINIB	ChEMBL	Phase 4 (approved)	MET
GILTERITINIB	ChEMBL	Phase 4 (approved)	ALK
LORLATINIB	ChEMBL	Phase 4 (approved)	ALK
NERATINIB	ChEMBL	Phase 4 (approved)	MET
OSIMERTINIB	ChEMBL	Phase 4 (approved)	ALK
REPOTRECTINIB	ChEMBL	Phase 4 (approved)	ALK
RUXOLITINIB	ChEMBL	Phase 4 (approved)	ALK
SORAFENIB	ChEMBL	Phase 4 (approved)	MET
TEPOTINIB	ChEMBL	Phase 4 (approved)	MET
TIVOZANIB	ChEMBL	Phase 4 (approved)	MET
UPADACITINIB	ChEMBL	Phase 4 (approved)	ALK
ALVOCIDIB	ChEMBL	Phase 3	ALK
DOVITINIB	ChEMBL	Phase 3	ALK
ENZASTAURIN	ChEMBL	Phase 3	MET
EPIGALOCATECHIN GALLATE	ChEMBL	Phase 3	MET
LINSITINIB	ChEMBL	Phase 3	MET
POZIOTINIB	ChEMBL	Phase 3	MET
RIGOSERTIB	ChEMBL	Phase 3	MET